Advanced Solid Tumors and Hematologic Malignancies
Cyclacel Limited focuses on advanced solid tumors and lymphoma, with clinical activity spanning locally advanced, recurrent, and metastatic disease. Its research includes b-cell lymphoma and t-cell lymphoma, reflecting interest in both solid and blood cancers that have limited treatment options.
- Advanced solid tumors
- Lymphoma
- Metastatic disease
- Refractory cancer
The sponsor’s oncology portfolio is centered on patients whose disease has progressed after standard therapies or for whom established treatment options are lacking.
Gynecologic and Breast Cancer
The company’s studies include multiple gynecologic cancers such as endometrial cancer and ovarian cancer, alongside breast cancer subtypes including triple-negative breast cancer, HER-2 refractory metastatic breast cancer, and hormone receptor-positive, HER-2 negative disease.
- Endometrial cancer
- Ovarian cancer
- Breast cancer subtypes
- Metastatic HER-2 refractory disease
These areas show a clear therapeutic interest in difficult-to-treat malignancies with substantial unmet clinical need.
Hepatobiliary and Gastrointestinal Oncology
Cyclacel Limited also targets biliary tract cancer, hepatocellular carcinoma, and metastatic colorectal cancer, extending its oncology research into hepatobiliary and gastrointestinal tumor types.
- Biliary tract cancer
- Hepatocellular carcinoma
- Metastatic colorectal cancer
- Solid tumor basket cohorts
Its basket-style clinical interest includes tumor types linked by a shared mechanism of action, broadening the scope of investigation across related cancers.
Targeted Oncology Mechanisms
The sponsor’s research landscape includes PLK1 inhibition and CDK2/9 inhibition, indicating a strong focus on cell-cycle and transcriptional control pathways in cancer.
- PLK1 inhibitor research
- CDK2/9 inhibitor research
- Cell-cycle regulation
- Transcriptional pathway targeting
These therapeutic interests align with its work in advanced malignancies where pathway-directed treatment strategies are being explored.
